EGFR and non-small cell lung carcinoma: Consistent with these observations, we find that in patients with EGFR mutant NSCLC, ATM activation is observed in tumors treated with EGFR inhibitor therapy, and progression-free survival is extended when tumors harbor co-occurring ATM loss-of-function mutations.